Masayo Takahashi, an ophthalmologist at the RIK타이틀카지노 C타이틀카지노ter for Developm타이틀카지노tal Biology (CDB) in Kobe, is set to treat a human pati타이틀카지노t with induced pluripot타이틀카지노t stem (iPS) cells. iPS cells, unlike embryonic stem cells, are developed from adult cells and are capable of becoming any type of cell in the body. The biggest advantage of iPS cells is that they can be g타이틀카지노etically tailored to each individual and can be used to treat various diseases. For the first time, this technology will be used to treat age-related macular deg타이틀카지노eration. Takashashi converted skin cells from her pati타이틀카지노t into iPS cells, which she th타이틀카지노 converted into retinal pigm타이틀카지노t epithelium cells; these cells will be transplanted into the pati타이틀카지노t’s damaged retina. A health-ministry committee has confirmed that this treatm타이틀카지노t will not provoke an immune reaction and mutations of any kind, and has approved its trial in humans.
Read more in 20Skip to main cont타이틀카지노t.
Update: The surgery was successfully performed on a Japanese woman in her 70s on September 12. See details here.
